Clinical Trial: Tegoprazan-Based Therapies for H. Pylori Eradication: A Randomized Controlled Trial
Study Status: COMPLETED
Recruit Status: COMPLETED
Condition: Helicobacter Pylori Eradication
Study Type: INTERVENTIONAL
Official Title: Efficacy and Safety of Tegoprazan-Based Dual, Triple, and Quadruple Therapies as First-Line Regimens for Helicobacter Pylori Eradication: A Prospective Randomized Controlled Trial
Brief Summary:
Current first-line Helicobacter pylori eradication protocols involve multidrug regimens comprising a proton pump inhibitor (PPI) or bismuth agent combined with dual antibiotics (e.g., clarithromycin, amoxicillin, quinolones, furazolidone, nitroimidazoles, or tetracycline) administered for 7-14 days.In China, the bismuth-containing quadruple therapy (BQT) remains the standard first-line treatment for H. pylori infection.However, BQT implementation is challenged by polypharmacy burdens, substantial adverse events,…
Read more